md-medicaldata

Authors

 

Mirjana Tomić¹, Dragan Tešić^1,3, Milena Mitrović^1,3, Radoslav Pejin^1,3, Dragica Andrić², Stefan Andrić <sup>2

1</sup>Klinički centar Vojvodine, Hajduk Veljkova 1, 21000 Novi Sad, Srbija
²Institut za kardiovaskularne bolesti Vojvodine, Put doktora Goldmana 4, 21204 Sremska Kamenica, Vojvodina, Srbija
³Univerzitet u Novom Sadu, Medicinski fakultet, Hajduk Veljkova 1, 21000 Novi Sad, Srbija

 

UDK: 616-008.6:577.112
616.633:577.112

The paper was received / Rad primljen: 09.05.2019.

Accepted / Rad prihvaćen: 14.05.2019

 

Correspondence to:

Mirjana Tomić
Klinički centar Vojvodine
Hajduk Veljkova 1, 21000 Novi Sad, Srbija,
Tel: +38163566344
e-mail: tesicmima@gmail.com

 

 

Abstract

 

Diabetic nephropathy, in its natural course, is initially manifested by the appearance of proteinuria. The aim of this  study was to establish the presence of classical risk factors in patients with diabetes (DM), divided into groups according to severity of proteinuria. Patients with proteinuria (PRU) 50-149.9 mg/24h included n1 = 180, those with PrU 150- 499.9 mg/dU n2= 165 and n3=99 with PrU <50mg/dU. The last ones were a control group. All values ​​are expressed in a median value (middleof the sequencenumbers). Patients with initial proteinuria had a later beginning of DM (39 vs. 33 yrs; p <0.05) and elevated levels of triglycerides (1.38 vs. 1.23 mmol/l) than the control group, with statistical significance. The tendency of significance showed at age (49 vs. 46yrs; p=0.08) and BMI (26.3 vs. 25.4 kg/m2; p=0.06). A group of subjects who had a clear proteinuria comparing to the control group of patients with normoproteinuria was significantly older (54 vs. 46yrs; p <0.01) and lower (165 vs. 168cm; p= 0.01), BMI (26.9 vs. 25.4kg/m2; p <0.01), with fewer injections of insulin (1 vs. 2), with later onset diabetes (41 vs. 33yrs; p <0.01), with higher systolic (140 vs. 130 mmHg) and diastolic pressure (85 vs. 80mmHg), triglycerides (1.64 vs.1.23 mmHg; p=0.01), type 2 diabetes vs. type 1 (60 vs. 44.5%). Based on the obtained results it can be concluded that the initial pathological proteinuria values are ​​characteristic of type 2 diabetes and are associated with hypertriglyceridemia and hypertension, and less intensive insulin treatment in patients translated into insulin therapy.

 

 

Keywords:

hypertension, triglyceridemia, obesity, diabetes, proteinuria

 

 

Sažetak

 

Dijabetesna (DM) nefropatija, u svom prirodnom toku, inicijalno se manifestuje pojavom proteinurije. Cilj rada bio je da se kod dijabetesnih bolesnika (DM), razvrstanih na grupe po izraženosti proteinurije, ustanovi prisustvo klasičnih faktora rizika. Bolesnika sa proteinurijom (PrU) 50-149.9mg/24h uključeno je n1= 180,onih sa  PrU 150-499,9 mg/dU n2= 165 i n3=99 sa PrU <50mg/dU. Ovi poslednji su ujedno bili i  kontrolna grupa. Sve vrednosti su izražene sa medijanom (srednjim članom ispitivanog niza brojeva). Bolesnici sa inicijalnom proteinurijom od kontrolne grupe značajno su se razlikovali po kasnijem početku DM (39 vs. 33 god.; p <0.05) i povišenim vrednostima triglicerida (1.38 vs. 1.23 mmol/l).  Tendenciju značajnosti je pokazivala starost (49 vs. 46god.; p=0.08) i BMI (26.3 vs. 25.4 kg/m2; p=0.06). Grupa ispitanika koji su imali jasnu proteinuriju je u odnosu na kontrolnu grupu, normoproteinuričnih bolesnika, bila značajno starija (54 vs. 46god.; p<0.01), niža (165 vs. 168cm; p= 0.01), BMI (26.9 vs. 25.4kg/m2; p <0.01), sa manjim brojem injekcija insulina (1 vs. 2), sa kasnijim početkom dijabetesa (41 vs. 33god.; p <0.01), sa višom sistolnom (140 vs. 130 mmHg) i dijastolnom tenzijom (85 vs. 80mmHg), trigliceridima (1.64 vs.1.23mmol/L; p=0.01), tip 2 dijabetesa vs. tip 1 (60 vs. 44.5%). Na osnovu dobijenih rezultata može se zaključiti da su početne patološke vrednosti proteinurija karakteristika tipa 2 dijabetesa sa pridruženom i povišenim vrednostima triglicerida i hipertenzijom, te manje intenzivnim insulinskim tretmanom u bolesnika prevedenih na insulinsku terapiju. 

 

 

Ključne reči:

hipertenzija, trigliceridemija, gojaznost, šećerna bolest, proteinurija.

 

 

References:

 

1. Eknoyan G1, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the NationalKidney Foundation (NKF) and the National In-stitute of Diabetes and Digestive and KidneyDiseases (NIDDK). Am J Kidney Dis 2003;42:617–22.
2. Kramer HJ, Nguyen QD, Curhan G, Hsu C-Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273–7.
3. Parving HH: Diabetic nephropathy: Prevention and treatment. Kidney Int 2001; 60:2041–55.
4. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renal protective benefits of renin-angiotensin system inhibition. AnnIntern Med 2002;136:604–15.
5. Keane WF1, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al: The risk of devel-oping end-stage renal disease in patients with type 2 diabetes andnephropathy: The RENAAL Study. Kidney Int 2003; 63:1499–507.
6. Krolewski AS1, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226–34.
7. Tuttle KR, Bakris GL2, Bilous RW3, Chiang JL4, de Boer IH5, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37:2864–83.
8. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849–61.
9. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal
10. insufficiency. Diabetes Care 2011;34:1431–7.
11. Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS. Improved glycemic
12. control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol. 2014 Dec;25(12):2916-25.
13. Heart Outcomes Prevention EvaluationStudy Investigators. Effects of ramipril on car-
14. diovascular andmicrovascular outcomes in people with diabetes mellitus: results of the HOPE
15. study and MICRO-HOPE substudy. Lancet 2000; 355:253–9.
16. Wheeler ML, Dunbar SA, Jaacks LM, Karmally W, Mayer-Davis EJ, Wylie-Rosett J, et al.Macronutrients, food groups, and eating pat-terns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care 2012;35:434–45.
17. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al.  Effect of intensive treat ment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419–30. 
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8.
19. Levey AS, Bosch JP, Lewis JB, Greene T,Rogers N, Roth D. Modification of diet in renal
20. disease study group. A more accurate method to estimate glomerular filtration rate from se-
21. rum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–70.

PDF Mirjana Tomić • MD-Medical Data 2018;10(4): 173-177